Our role in the fight against AMR
Antimicrobial resistance (AMR) is an urgent issue requiring action now.
Rates of AMR have been rising and each day nearly 100 people die of resistant infections in Europe1.
We are determined to be part of the solution. As part of our ongoing efforts in this crucial area, we:
· invest the highest proportion of our pharmaceutical revenues in relevant anti-infectives research and development compared with other large pharmaceutical companies.2
· are expanding our capabilities – Shionogi has entered into a definitive agreement to acquire Qpex Biopharma, Inc. Qpex’s pipeline and its capabilities will accelerate our efforts to develop new antibiotic treatments to address antimicrobial resistance.
· are a signatory company of the Davos Declaration on combating AMR, which calls for collective action to create a sustainable and predictable market for antibiotics, vaccines and diagnostics.3
· take action to help reduce overuse of antibiotics, such as securing landmark deals in European countries (including the UK and Sweden) that break the links between the payments received and the number of antibiotics prescribed.4,5
· are a sponsor and contributor to the Vivli AMR Register project which sees pharmaceutical companies facilitate access to resistance surveillance data on their antibiotics.6
· are proud that globally, Shionogi works with the Global Antibiotic Research and Development Partnership (GARDP) and the Clinton Health Access Initiative (CHAI), to improve and accelerate access to newer antibiotics for countries around the world.7
· brought together experts for a dedicated session at this year’s European Health Forum Gastein, alongside Carb-X, to dig deeper into the required action.
Find out more about AMR and the potential solutions in this feature produced for us and a number of other partners by BBC StoryWorks and presented by the AMR Action Fund: HERE